Login to Your Account

Phase II NSCLC Data Send Peregrine Shares Jumping

By Staff Reports

Wednesday, December 7, 2011
Shares of Peregrine Pharmaceuticals Inc. spiked 21 percent after the Tustin, Calif.-based firm reported a 50 percent improvement in overall response rate (ORR) in a Phase II study testing bavituximab in non-small-cell lung cancer (NSLCL).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription